Kymera Therapeutics

15 articles with Kymera Therapeutics

• Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/17/2019

  Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.

• Kymera Therapeutics Announces Leadership Transitions

  7/15/2019

   Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create breakthrough therapies for previously untreatable diseases, today announced key leadership transitions

• Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

  6/19/2019

  KYM-001 causes potent and selective IRAK4 protein knockdown and regression of OCI-LY10 tumor xenografts, both alone and in combination with BTK inhibition

• Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

  5/15/2019

  Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines

• 

  Vertex Establishes $70 Million Protein Degradation Partnership with Kymera Therapeutics

  5/15/2019

  The move by Vertex is part of the company's plan to diversify its drug discovery strategies.

• Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

  3/29/2019

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma

• Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

  12/18/2018

   Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the expansion of its Scientific Advisory Board (SAB) to support development of the company's Pegasus platform and advancement of its small molecule-based protein degrader therapeutics into the clinic.

• Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma

  12/3/2018

  Data Presented at the 2018 American Society of Hematology Annual Meeting

• 

  With $65 Million in Hand, Kymera Will Put Its Protein Degradation Technology to the Test

  11/13/2018

  Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.

• Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

  11/13/2018

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.

• 

  BioSpace Movers and Shakers Sept. 24

  9/24/2018

  Here's a look at who's making moves in the biotech and pharma world this week.

• Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

  9/20/2018

  Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer.

• 

  Arvinas to Launch IPO to Raise $100 Million

  8/31/2018

  New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.

• Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality

  4/4/2018

  Collaboration to Accelerate the Discovery of Protein Degrading Therapeutics

• Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer

  2/6/2018

  Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience.